Athira Pharma’s stock price fell 81% as its lead fosgonimeton treatment for Alzheimer’s disease failed its phase II/III LIFT-AD clinical trial. The drug did not meet the trial’s primary or key secondary endpoints. However, chief medical officer Javier San Martin said Athira planned to continue developing fosgonimeton, citing preliminary results from various subgroups.

StockWatch: Sarepta CEO Defends Elevidys as Q4 Sales Fall Short
SAN FRANCISCO—No sooner did the J.P. Morgan 44th Annual Healthcare Conference kick off when Sarepta Therapeutics (SRPT) saw its stock skid 11% after the company